ELEMENT MATERIALS TECHNOLOGY IOWA CITY INC.

Element Materials Technology Iowa City Inc. specializes in in vitro antimicrobial research and laboratory testing focused on bacterial pathogens, with deep expertise in determining minimal inhibitory concentrations (MIC), screening antibacterial activity, and evaluating the inhibitory effects of experimental compounds against high-priority public health threats such as Neisseria gonorrhoeae and other gram-negative organisms. The contractor delivers precise, reproducible microbiological assays using standardized clinical and research protocols, supporting the development of novel therapeutics and resistance profiling. Their technical proficiency spans antimicrobial susceptibility testing, culture-based pathogen characterization, and high-throughput screening methodologies, positioning them as a trusted partner for early-stage antibacterial discovery and evaluation. The company maintains a consistent, long-standing relationship with the Department of Health and Human Services, delivering mission-critical biotechnological research and laboratory services under multiple task orders. Their work directly supports HHS objectives in combating antimicrobial resistance, informing public health responses, and advancing next-generation antimicrobial agents through rigorous in vitro data generation. Element’s primary industry focus is in research and development in biotechnology, specifically non-nanotechnology applications related to infectious disease therapeutics. They operate at the intersection of pharmaceutical R&D and public health surveillance, serving as a specialized contract research organization for antimicrobial evaluation. Their niche lies in targeted compound screening against clinically relevant bacterial isolates, distinguishing them from broader biotech service providers. As a small business with a 2L structure based in North Liberty, Iowa, the company operates with a focused, mission-driven approach. While no formal government certifications are currently listed, their consistent delivery of complex, high-precision laboratory services to federal health agencies demonstrates a proven track record of compliance, scientific rigor, and operational reliability within the federal biotechnology research ecosystem.